15 results about "Peptide formation" patented technology

The invention discloses an application of a CD177 targeted membrane modified liposome in preparation of a medicine for preventing and / or treating psoriasis. The structure of the CD177 targeting membrane modified liposome comprises a PADI4 inhibitor loaded liposome, a targeting recognition layer formed by coupling CD177 targeting peptide on the surface of the liposome, and a bionic functional layer formed by coating a natural neutrophile granulocyte membrane on the outermost layer. Based on the core pathological mechanism of 'CD177 + neutrophil-NETs' of psoriasis, the inflammation chemotaxis / cell factor neutralization function of a neutrophil membrane, the precise targeting function of CD177 peptide and the NETs inhibition function of a PADI4 inhibitor are creatively and organically integrated, and the constructed GNLC achieves the synergistic treatment effect of 'targeting enrichment-mechanism blocking-microenvironment remodeling'; meanwhile, excellent stability and safety are achieved, and a new precise treatment strategy far better than that in the prior art is provided for psoriasis.

An object of the present invention is to provide a cell aggregate-inducing peptide, a cell aggregate-forming agent containing the same, and a method for forming a cell aggregate using the same.SOLUTION: A cell aggregate-inducing peptide represented by General Formula (1), having hydroxypipecolic acid and lysine as constituent repeating units. (HPA-Lys) n. (1) [In the general formula (1), HPA represents hydroxypipecolic acid, Lys represents lysine, and n is an integer of 4 or more and 30 or less.]. ] SELECTED DRAWING: None

The invention discloses an electrochemical sensor for glycoprotein detection and a glycoprotein detection method. The method comprises the following steps: anchoring an aptamer-protein conjugate on the surface of a gold electrode, and then assembling an anti-fouling peptide around the aptamer-protein conjugate to form an imprinted self-assembled monolayer film. And removing the combined protein through an acid solution to form a biocompatible imprinting cavity capable of being used for recombining a target object. The imprinted cavity can eliminate non-specific adsorption and enhance targeted binding efficiency. The sensor can be used for directly detecting carcino-embryonic antigens with the concentration as low as 0.1 ng / mL through an electrochemical impedance spectroscopy method. Besides, homodimer concanavalin A (ConA) is used as a recognition element and a cross-linking agent, homodimer glucose oxidase (GOx) is assembled on the surface of the electrode in situ, a protein network can be formed, and enzyme catalysis signal amplification detection is achieved. Through in-situ formation of a ConA-GOx assembly, the sensitivity is improved by 100 times.

The invention discloses probucol nano targeting particles as well as application and a pharmaceutical composition thereof, and relates to the technical field of pharmacy. The probucol nano targeting particle comprises a polymer formed by Poly (HPDMA-RSM)-PEG-NHS and a kidney targeting peptide, wherein the sequence of the kidney targeting peptide is KCSAVPLC, and the sequence of the kidney targeting peptide is KCSAVPLC. And probucol; wherein in the probucol nanometer targeting particle, the hydrophobic segment of the polymer and probucol are aggregated to form a solid core, the hydrophilic PEG chain of the polymer extends outwards to form a hydration shell layer, and the kidney targeting peptide is exposed on the surface of the probucol nanometer targeting particle. According to the invention, Probucol is encapsulated in PEG nanoparticles coupled with KTP for the first time, so that (1) accurate enrichment of renal tubular epithelium is realized; (2) the ferroptosis pathway is efficiently inhibited; (3) the curative effect is obviously improved. The strategy shows a synergistic protection effect superior to that of a naked drug and other antioxidants in a cis-platinum induced AKI model, and has outstanding creativity and industrial transformation value.

The present invention relates to a method for forming a conjugate of a desired target substance and a peptide. A method according to the present invention includes a step for bringing a genetic information material-linker-peptide conjugate into contact with a target substance conjugate containing at least two target substances. The genetic information material-linker-peptide conjugate includes: (a) a linker that includes a bond portion having a structure capable of binding to a desired genetic information material and includes at least two puromycin-like substances, the puromycin-like substances being capable of covalently binding to the C-terminus of a desired peptide; (b) a genetic information material that is bonded to the bond portion of the linker of (a); and (c) a peptide that is bonded to at least two or more puromycin-like substances of the linker of (a) and is encoded by the genetic information material.

The invention discloses an application of a CD177 targeted membrane modified liposome in preparation of a medicine for preventing and / or treating systemic lupus erythematosus. The structure of the CD177 targeting membrane modified lipidosome is divided into three layers, and comprises a lipidosome loaded with a PADI4 inhibitor, a targeting recognition layer formed by coupling CD177 targeting peptide on the surface of the lipidosome, and a bionic functional layer formed by coating a natural neutrophile granulocyte membrane on the outermost layer. In an imiquimod (IMQ)-induced lupus model, the medicine treatment shows strong disease remission capability: 1) improving the whole body phenotype: obviously reducing the swollen spleen and lymph node of lupus mice; 2) repairing kidney functions: significantly relieving glomerulonephritis, and reducing inflammatory cell infiltration and IgG and complement C3 deposition in glomerulus, and 3) significantly reducing the level of proinflammatory cytokines in serum and the titer of a lupus marker anti-dsDNA antibody.

This invention discloses a system for rapid detection of tumor cell invasiveness and risk level reference based on matrix remodeling fluorescence reporter assay. After staining, test cells are seeded on a matrix material formed by cell adhesion ligands and fluorescent dye-modified polyisocyanate peptides for 2D culture, or the two components are thoroughly mixed and gelled to form a 3D culture environment, resulting in a cell-induced matrix remodeling fluorescence detection system. Fluorescence images of the area surrounding the sample are acquired, and cell invasiveness risk is analyzed based on changes in the intensity of the fluorescence signal in the surrounding area and the matrix remodeling index. This invention provides a more direct and rapid assessment of tumor cell invasiveness by observing the matrix remodeling characteristics induced during cell invasion in real time in vitro, providing a risk level reference for tumor malignancy.

In various aspects, the present disclosure provides methods for forming radiopaque peptides that comprise one or more iodinated amino acid residues and one or more amine-based amino acid residues. Typically, the peptides contain from 3 to 20 amino acid residues. The present disclosure relates to methods of forming such radiopaque peptides, to the use of such radiopaque peptides as crosslinking agents for forming hydrogels, and to hydrogels formed from such radiopaque peptides. The radiopaque peptides and hydrogels are useful, for example, in various medical applications.

Disclosed herein are peptides compounds which are capable of forming collagen mimetic biomaterials. In some embodiments, the presently disclosed peptides may be stabilized by cation-pi interactions or by covalent interactions involving levodopa residues. In some embodiments, the present disclosure provides higher order structures formed from the peptides disclosed herein, including homotrimers, heterotrimers, and hydrogels.

Triple G-C-T base coded nucleobase amino acids according to Formula (I):wherein R is —H or -Boc, are provided as building blocks for peptide sequences. The compound of formula (I) includes three recognition sites, DDA (G mimic), DAA (C mimic) and ADA (T mimic) that can simultaneously interact with two sets of nucleobases (C-A or G-A), at any given time. A one-step synthetic process for the triple G-C-T base coded nucleobase amino acids is provided.

In various aspects, the present disclosure provides methods for forming radiopaque peptides that comprise one or more iodinated amino acid residues and one or more amine-based amino acid residues. Typically, the peptides contain from 3 to 20 amino acid residues. The present disclosure relates to methods of forming such radiopaque peptides, to the use of such radiopaque peptides as crosslinking agents for forming hydrogels, and to hydrogels formed from such radiopaque peptides. The radiopaque peptides and hydrogels are useful, for example, in various medical applications.

This invention discloses a membrane-modified liposomal drug targeting CD177-positive neutrophils and its preparation method. The membrane-modified liposomal drug has a three-layer structure, including: a liposome loaded with a PADI4 inhibitor, a targeting recognition layer formed by coupling a CD177 targeting peptide to the surface of the liposome, and an outermost biomimetic functional layer formed by coating the natural neutrophil membrane. Based on the key pathological mechanism of the "CD177-NETs axis," this invention designs a structurally sound, safe, and stable biomimetic targeted nanoformulation. It creatively combines the anti-inflammatory / chemotactic function of the neutrophil membrane, the precise targeting of the CD177 peptide to pathogenic subgroups, and the source blocking of NETs by the PADI4 inhibitor, achieving highly efficient dual-targeted enrichment and synergistic therapy.

This invention belongs to the field of environmental monitoring and analytical chemistry technology, and provides a rapid detection method and kit for polystyrene microplastics based on a sandwich method. It includes: a capture component, a magnetic bead-peptide conjugate with a specific peptide covalently coupled to it; and a detection component, a luminescent detection probe formed by covalently coupling bovine serum albumin with a chemiluminescent label and the specific peptide; the specific peptide has an amino acid sequence as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5. The peptide of this invention possesses extremely strong specific binding ability, which can reduce cross-reactions by precisely matching the microplastic target structure, thereby improving detection specificity from the root cause; the use of magnetic beads to load the peptide, with the ultra-large specific surface area of ​​the magnetic beads, can significantly improve the binding efficiency between the peptide and the microplastic; combined with the luminescent group or fluorescent group coupled to the peptide, no additional enzyme-labeled secondary antibody incubation and enzyme-catalyzed colorimetric reaction are required.

The invention discloses an application of a CD177 targeted membrane modified liposome in preparation of a medicine for preventing and / or treating rheumatoid arthritis. The structure of the CD177 targeting membrane modified liposome comprises a PADI4 inhibitor loaded liposome, a targeting recognition layer formed by coupling CD177 targeting peptide on the surface of the liposome, and a bionic functional layer formed by coating a natural neutrophile granulocyte membrane on the outermost layer. Based on the core pathological mechanism of RA 'CD177 + neutrophil-NETs', the inflammation chemotaxis / cell factor neutralization function of a neutrophil membrane, the synovial membrane pathogenic cell precise targeting function of CD177 peptide and the NETs source blocking function of a PADI4 inhibitor are creatively and organically integrated; the constructed GNLC realizes a synergistic treatment effect of joint targeted enrichment-pathological mechanism blocking-synovial microenvironment remodeling, and also has excellent stability and long-term safety.

The application provides a kind of iron-binding peptide based on tuna blood meat, wherein the amino acid sequence of some polypeptides is SEQ ID NO:1-6.The polypeptide provided by the application can be used to prepare a preparation for treating iron deficiency anemia.The tuna red meat blood peptide provided by the application can be used to prepare a blood supplement preparation, and through specific polypeptide iron ion chelation, a high-bioavailability organic iron complex is formed, which significantly improves the absorption efficiency of iron in the intestinal tract.The carrier formed by the polypeptide can protect iron ions from being destroyed by gastric acid and target delivery to the absorption site, so that the hemoglobin synthesis efficiency is increased by more than 40%.The natural polypeptide ligand of the application avoids the gastrointestinal irritation of traditional iron supplements and is not affected by dietary factors such as phytic acid and tannin absorption interference.Functional blood supplement peptides are prepared from tuna processing by-products, which not only realizes the high-value utilization of fishery resources, but also provides an ecological-friendly new source of iron supplement.